The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
LLM 2021 | Treatment strategies for recurrent CLL
Michael Choi, MD, UC San Diego Health, San Diego, CA, describes the treatment landscape for patients with recurrent chronic lymphocytic leukemia (CLL). Treatment strategies available for this patient population include Bruton’s tyrosine kinase (BTK) and Phosphatidylinositol 3-kinase (PI3K) inhibitors, BCL2 inhibitors, and chemoimmunotherapy regimens. However, studies such as the MURANO (NCT02005471) and RESONATE (NCT01578707; NCT01722487) trials have shown that targeted therapies are more effective than chemoimmunotherapy. Cellular therapies, particularly CAR T-cells, are also a potential treatment option for CLL patients progressing on BCL2 and BTK inhibitors. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
